Pulmonx to Present at Upcoming Investor Conferences

Rhea-AI Summary

Pulmonx Corporation (NASDAQ: LUNG) announced its participation in two virtual investor conferences. The company will present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 10:40 a.m. ET, with a live and archived webcast available on its website. Additionally, Pulmonx management will join investor meetings at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020. Pulmonx specializes in minimally invasive treatments for severe emphysema, having received FDA pre-market approval for its Zephyr Endobronchial Valve.

REDWOOD CITY, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) today announced the company will be participating in two upcoming virtual investor conferences.

Pulmonx management is scheduled to present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 10:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the event on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

Pulmonx management will also be participating in investor meetings at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020.

About Pulmonx
Pulmonx^® Corporation (NASDAQ: LUNG) is a commercial-stage medical technology company that provides minimally invasive treatment for patients with severe emphysema, a form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform, is designed to treat severe emphysema/COPD patients who, despite medical management, are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device”. The Zephyr Valve is commercially available in more than 25 countries, with over 80,000 valves used to treat more than 20,000 patients. For more information on the Zephyr Valves please visit www.MyLungsMyLife.com. For more information on the company, please visit www.Pulmonx.com.

Pulmonx, Chartis^®, StratX^®, and Zephyr^® are registered trademarks of Pulmonx Corporation.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com

 

FAQ

When is Pulmonx presenting at the Stifel 2020 Virtual Healthcare Conference?

Pulmonx will present on November 16, 2020, at 10:40 a.m. Eastern Time.

Where can I access the Pulmonx conference presentation?

The presentation will be available via live and archived webcast on the Investors section of the Pulmonx website.

What is the focus of the Canaccord Genuity Virtual MedTech & Diagnostics Forum?

Pulmonx management will participate in investor meetings during the forum on November 19, 2020.

What is the significance of the Zephyr Endobronchial Valve?

The Zephyr Valve is a minimally invasive treatment approved by the FDA for severe emphysema patients.

How many countries is the Zephyr Valve available in?

The Zephyr Valve is commercially available in over 25 countries.